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An anti-CD5 monoclonal antibody ameliorates proteinuria and
glomerular lesions in rat mesangioproliferative glomerulonephritis
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An anti-CD5 monoclonal antibody ameliorates proteinuria and the local cell-mediated mechanism of lymphocyte induc-
glomerular lesions in rat mesangioproliferative glomerulone- tion may play a role in the pathogenesis of proliferative
phritis.
and nonproliferative nephritis [7]. An influx of lympho-Background. Increased numbers of lymphocytes have been
cytes has also been demonstrated in several experimentalidentified in biopsy specimens of human mesangial prolifera-
tive glomerulonephritis (GN). However, the causal relationship models of GN, involving either autologous immune reac-
between infiltrating T lymphocytes and mesangial changes in tion-mediated models induced by immunization with en-
mesangial proliferative GN has not been previously evaluated.
dogenous or exogenous antigen [8, 9] or passive-type mod-In this study, we elucidated the role of lymphocytes in the
els induced by the injection of antiglomerular componentdevelopment of mesangial proliferative GN.
Method. Immunohistological and flow cytometric analyses antibody [10, 11]. Lakkis et al demonstrated that high
as well as a reverse transcription-polymerase chain reaction (RT- numbers of CD431 cells (T lymphocytes) were recruitedPCR) studies were performed in monoclonal antibody (mAb)
into glomeruli just after heterologous injection of anti-1-22-3–induced Thy 1.1 GN. To elucidate the role of these lym-
phocytes, depletion studies were carried out using anti-CD8 glomerular basement membrane (GBM), although the
mAb (OX-8), which depletes both CD81 T lymphocytes and recruitment mechanism was unknown [11]. They also
natural killer (NK) cells and anti-CD5 mAb (OX-19), which showed that mRNA levels of T-helper (Th)1-type anddepletes both CD41 and CD81 T lymphocytes.
Th2-type lymphokine were already increased 24 hoursResults. Immunofluorescence (IF) studies revealed that NK
cells and CD41 T lymphocytes were recruited into glomeruli. after anti-GBM injection, and suggested that Th lympho-
Glomerular mRNA expression for interferon-g, interleukin-2 cyte subsets modulate glomerular inflammation. In some
(IL-2), IL-10, and perforin increased after induction of GN.
experimental models, it has been reported that not onlyIncreased expressions of several chemokines, which have the
antigen-specific, but also non–antigen-specific T lympho-potential to attract lymphocytes, were also detected. Anti-CD8
mAb treatment completely prevented the recruitment of NK cytes are recruited into site of inflammation and that
cells; however, it had no protective effect on proteinuria and they might be involved in disease progression [7, 12, 13].
mesangial injury. By contrast, anti-CD5 mAb treatment sup-
Recently, Shimamine et al reported that anti-CD81 Tpressed the recruitment of CD41 T lymphocytes into glomeruli
lymphocyte treatment exerted a protective effect againstand reduced proteinuria (60.4 6 25.7 vs. 120.0 6 32.3 mg/day,
P , 0.05) and mesangial changes evaluated by total number mesangial injury without reducing IgA deposition in the
of cells in glomeruli (63.2 6 6.0 vs. 81.4 6 5.9, P , 0.01) and mesangium in ddY mice, an animal model of spontane-
a-smooth muscle actin staining score (1.4 6 0.2 vs. 2.2 6 0.4,
ous IgA nephropathy [14]. They suggested that CD81 TP , 0.01) on day 14 after induction of GN. mRNA expression
for IL-2 was significantly reduced by OX-19 treatment. lymphocytes in glomeruli, in which antigen specificity
Conclusion. T lymphocytes participate in the development was not identified, have an important role specifically in
of mesangial proliferative GN.
mesangial proliferation.
Thy 1.1 GN is induced by passive injection of anti-
Thy 1.1 antibody and is characterized by an early phaseIncreased numbers of lymphocytes have been identi-
of inflammatory cell infiltration, including polymorpho-fied in biopsy specimens of several types of human glo-
nuclear cells and monocytes/macrophages, followed bymerulonephritis (GN) [1–6], and it has been suggested that
mesangial cell proliferation and mesangial matrix expan-
sion [15, 16]. Thy 1.1 GN is considered to be one of theKey words: T lymphocyte, macrophage, Thy 1.1 glomerulonephritis,
kidney lesions, proteinuria, nephropathy, inflammation. best models for analyzing the mechanism of progressive
mesangial injury. We have been studying the pathogene-Received for publication May 27, 1999
sis of Thy 1.1 GN induced by anti-Thy1.1 monoclonaland in revised form January 6, 2000
Accepted for publication January 20, 2000 antibody (mAb) 1-22-3 [17–19]. Previously, we reported
that lymphocyte infiltration was already detectable twoÓ 2000 by the International Society of Nephrology
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hours after mAb 1-22-3 injection and that an increased To determine the nature of the cytokines considered
to be produced by lymphocytes [interferon-g (IFN-g),number of lymphocytes were seen in the mesangial area
on day 6 with electron microscopy [20]. These lympho- interleukin (IL)-2, IL-4, IL-10, and perforin] and chemo-
kines, which are considered to attract lymphocytes [mono-cytes in the mesangial area seem to be involved in sub-
sequent mesangial proliferation. However, the causal cyte chemoattractant protein-1 (MCP-1), regulated on acti-
vation, normal T cell expressed and secreted (RANTES),relationship between infiltrating T lymphocytes and mes-
angial changes in mesangial proliferative GN has not and lymphotactin] [21–23], RT-PCR studies were per-
formed on glomerular RNA. The total glomeruli werebeen previously evaluated. In this study, we used immu-
nofluorescence (IF) with several mAbs to characterize isolated from pooled kidneys of five rats by a sieving
method [24].subpopulations of lymphocytes in glomeruli and periph-
eral blood and reverse transcription-polymerase chain Experiment 2: Lymphocyte depletion study. In vivo
T-cell depletion was induced by injections of the follow-reaction (RT-PCR) to analyze the expression of lympho-
kines. To examine if there is a causal relationship be- ing antilymphocyte antibodies: OX-19, which depletes
CD51 pan T lymphocytes [8, 25, 26], OX-38, which de-tween infiltrating T lymphocytes and mesangial changes,
we carried out depletion studies with OX-19 (reactive pletes CD41 T lymphocytes [10, 27, 28], and OX-8, which
depletes both CD81 T lymphocytes and NK cells [8, 10].with CD51 pan T cells), OX-38 (reactive with CD41 T
lymphocytes), or OX-8 [reactive with CD81 T lympho- As a control, murine IgG1 mAb, RVG1 (against rotavi-
rus) was used [29]. The rats were injected with mAbscytes and natural killer (NK) cells]. The results indicated
that infiltrating T lymphocytes were involved in the in- intraperitoneally (3 mg/100 g body weight) and intrave-
nously (1 mg/100 g body weight) simultaneously two daysduction of proteinuria and mesangial changes.
before the induction of GN.
A total of 60 rats was used in this experiment. For
METHODS
OX-19–depletion study, 20 rats were divided into an
Animals OX-19–treated group and a control group. Rats were
sacrificed on days 7 (N 5 5) and 14 (N 5 5), and kidneysAll experiments were performed using female Wistar
rats weighing 150 to 200 g and were purchased from were removed in the same manner as in experiment 1.
Twenty-four–hour urine samples were collected on daysCharles River Japan (Atsugi, Japan). All animal experi-
ments conformed to the National Institutes of Health 1, 3, 5, 7, 10, and 14 after injection of mAb 1-22-3. Urine
protein concentrations were determined by colorimetricGuide for the Care and Use of Laboratory Animals.
assay (BioRad, Oakland, CA, USA) using bovine serum
Experimental protocol albumin as a standard. OX-38 depletion and OX-8 deple-
tion studies were also designed as an OX-19-depletionExperiment 1: Examination of glomerular infiltration
by lymphocytes. Thy 1.1 GN was induced in 30 rats by experiment. Glomerular injury was assessed by LM, IF,
and kidney weight. The number of glomerular infiltratinga single injection with 1.0 mL saline containing 500 mg
of mAb 1-22-3 intravenously through the tail. Prepara- lymphocytes on day 7 was counted to assess the effects
of OX-8 treatment on the recruitment of lymphocytestion of mAb 1-22-3 and induction of Thy1.1 GN have
been described previously [17–20]. The rats were sacri- in glomeruli.
Flow cytometric analysis was carried out to assess theficed just before injection of mAb 1-22-3 and at 30 min-
utes and on days 1, 3, 7, and 14 after induction of GN effects of mAb treatments on circulating lymphocytes.
Five rats were used for each depletion group. To prepare(N 5 5 per time point). At each time point, the right
kidney was removed, weighed, and used to prepare the PBMCs, heparinized blood was obtained from each rat
on days 9 and 16 after antilymphocyte mAb treatments.total glomerular RNA. The left kidney was perfused via
the aorta with phosphate-buffered saline before being To further analyze the role of CD51 lymphocytes, 60
rats were divided into an anti-CD5 mAb (OX-19)–treatedremoved and then cut into portions and used for assess-
ment by light microscopy (LM) or IF. The presence of group and a control group treated with RVG1, a murine
mAb against rotavirus. The rats from each group werelymphocytes in glomeruli was determined by IF staining
using specific mAbs against rat lymphocyte antigens. sacrificed before injection and at 30 minutes and on days
1, 3, 7, and 14 after an injection of mAb 1-22-3 (N 5Flow cytometric analysis was carried out to analyze
the time course of the number of circulating lymphocyte 5 on each time point), and kidneys were removed as
described in experiment 1. The fixation of complementssubsets. Ten rats were divided into two groups, and
in each group, five rats each were injected with mAb in glomeruli was compared as described before [19]. The
decreased level of serum CH50 in each group was also1-22-3 or saline. To prepare peripheral blood mononu-
clear cells (PBMCs), heparinized blood was obtained compared 30 minutes after injection of mAb 1-22-3. The
time courses of glomerular infiltration of lymphocytesfrom each rat before injection, and on days 1, 3, 7, and
14 after injection of mAb 1-22-3. and monocytes/macrophages were compared by IF stain-
Ikezumi et al: Lymphocytes in Thy1.1 GN102
ing, with specific mAbs against rat lymphocytes antigen rescein isothiocyanate (FITC)-conjugated goat anti-
mouse IgG1 and FITC-conjugated goat anti-mouseand mAbs against macrophage subsets. At each time
point, expression of mRNA for lymphokines (IFN-g, IgG2a were used as secondary antibodies (Southern Bio-
technology Associates, Birmingham, AL, USA). TheIL-2, IL-10, and perforin), platelet-derived growth factor
(PDGF)-BB, and transforming growth factor-b (TGF-b) number of mononuclear cells per glomerular cross-sec-
tion (c/gcs) was counted in 50 randomly selected full-was also compared by RT-PCR on isolated glomeruli of
pooled kidneys from five rats. sized glomeruli by an observer who was unaware of the
experimental protocol. Double-staining IF studies withAnother set of experiments was carried out to quanti-
tate the glomerular mRNA for IL-2 and IFN-g. Ten rats OX-19 and OX-38, with OX-19 and R1-10B5 (IgG2a,
anti-CD8; Seikagaku Co., Tokyo, Japan), or with 10/78were divided into an anti-CD5 mAb-treated group and
a control group. Five rats of each group were sacrificed and R1-10B5 were performed. Tetramethyl-rhodamine
isothiocyanate (TRITC)-conjugated goat anti-mouseon day 14 after injection of mAb 1-22-3. Glomerular
RNA was prepared from each animal and was used for IgG1 (for OX-19 and 10/78) and FITC-conjugated anti-
mouse IgG2a (for OX-38 and R1-10B5) were used asthe RT-PCR study.
To compare the amounts of mAb 1-22-3 bound to the secondary antibodies (Southern Biotechnology Associ-
ates). Double staining with anti-rat perforin (Torreykidney, three rats from each group were injected with
mAb 1-22-3 labeled with 125I by the chlolamine-T method Pines Biolabs, Inc., San Diego, CA, USA), and 10/78
was performed using FITC-conjugated anti-rabbit IgG[30]. The radioactivity was measured with an autogamma
scintillation photometer (model 5260; Packard, Sterling, (Dako, Glostrup, Denmark) and TRITC-conjugated goat
anti-mouse IgG1 as secondary antibodies. To quantitateVA, USA) 30 minutes after injection.
the mesangial changes, frozen sections were stained with
Light microscopy anti-collagen type I (Chemicon) or a-smooth muscle ac-
tin (a-SMA; IgG2a; Sigma, St. Louis, MO, USA) anti-Tissue samples for light microscopic assessment were
fixed with 10% neutral-buffered formalin, embedded in bodies. The degree of collagen type I and a-SMA stain-
ing was scored 0 to 41 in 30 randomly selected glomeruliparaffin, cut into 4 mm sections, and stained with periodic
acid-Schiff (PAS) reagent. Semiquantitative morpholog- according to the method described by Floege et al [32].
FITC-conjugated anti-rabbit IgG was used as secondaryical studies of glomerular lesions were carried out by
randomly selecting 30 full-sized glomeruli (80 to 100 mm) antibody to detect rabbit anti-rat collagen type I. FITC-
conjugated anti-rat C3 (Cappel, West Chester, PA, USA)from each specimen. The sections were analyzed in a
double-blind manner, and the degree of glomerular mes- was used to assess the glomerular fixation of complement.
angial matrix expansion was scored 0 to 41 according
Flow cytometric analysisto the percentage of glomerular involvement, as de-
scribed by Raij, Azar, and Keane [31]. The total number The relative lymphocyte subset frequencies in the pe-
ripheral blood of rats were analyzed by flow cytometry.of cells in glomeruli was also counted in a blind protocol
and computed for 30 glomeruli for each kidney. To prepare PBMCs, heparinized artery blood was ob-
tained from tail arteries when the animals were under
Immunofluorescence general anesthesia. The total mononuclear cells in each
blood sample were counted in triplicate with a hemacy-Tissue samples for IF studies were snap frozen in pre-
cooled n-hexane and stored at 2708C. Frozen sections tometer after being diluted with Turk’s solution. The
contaminating erythrocytes in the cell preparation were3 mm thick were cut with a cryostat and stained with
specific mAbs to rat lymphocytes and monocytes/macro- lyzed by 0.85% ammonium chloride. FITC-conjugated
OX-19, OX-38, and OX-8 prepared as described by Ka-phages. Mouse anti-rat mAb OX-19 (IgG1, anti-CD5)
[8, 25, 26] was used as pan T-cell marker, OX-38 (IgG2a, wamura [33], and FITC-conjugated 10/78 (Serotec) were
used to detect lymphocyte subsets. Cytometric analysisanti-CD4) [10, 27, 28] as a T helper cell marker, OX-8
(IgG1, anti-CD8) [8, 10] as an T cytotoxic/suppressor of surface antigen expression was performed on a FACS-
can (Becton Dickinson, Mountain View, CA, USA). To-cell marker, and 10/78 (IgG1, anti-NKR-P1) as an NK
cell marker. OX-19, OX-38, and OX-8 were precipitated tal leukocytes were detected using the OX-30 mAb (anti-
leukocyte common antigen marker; Caltag, Burlingame,from ascites using the corresponding hybridoma (Euro-
pean Collection of Animal Cells, Porton Down, Salis- CA, USA), and RVG1 (mouse IgG1) was used as a
negative control.bury, UK); 10/78 was purchased from Serotec (Oxford,
UK). ED1 (IgG1, reactive with pan monocytes/macro-
RT-PCRphages) and ED3 (IgG2a, reactive with macrophage si-
aloadhesin) were used to detect monocytes and macro- Isolated glomeruli were immediately dissociated by
guanidinium and phenol extraction (TRIZOL; GIBCOphages purchased from Chemicon International Inc.
(Temecula, CA, USA) and Serotec, respectively. Fluo- BRL, Gaithersburg, MD, USA). Complementary DNA
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(cDNA) was synthesized using a commercial kit (Super-
Script Preamplification System; GIBCO BRL) following
the standard protocol. The primers were designed ac-
cording to published sequences (Table 1). Amplification
was carried out using the PC-800 programmable temper-
ature control system (Astec, Fukuoka, Japan) through
20 to 40 cycles of denaturation at 958C for 30 seconds,
annealing at individual temperatures for 30 seconds, and
extension at 728C for 10 minutes. The optimal cycle num-
bers were determined in a preliminary trial to be in
the linear phase of amplification. Amplification of the
housekeeping gene, glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH), was used as a positive control for
intact RNA and for measuring the efficiency of RT.
Negative controls without cDNA and positive controls
of cDNA from Con-A–stimulated rat spleen cells were
included in all experiments. The PCR products were
subjected to electrophoresis through 1.5% agarose gels
and were stained with ethidium bromide. The band in-
tensities were determined by image analysis using a Mac-
intosh computer and densitometry software (Densito-
graph; ATTO, Tokyo, Japan).
Statistical analysis
Statistical significance was evaluated using the unpaired
t-test or the Mann–Whitney U-test. Values were expressed
as the mean 6 SD. Differences at P , 0.05 were consid-
ered significant. Data were analyzed using StatView for
Macintosh (Abacus Concepts, Berkeley, CA, USA).
RESULTS
Experiment 1: Glomerular infiltration of lymphocytes
Significant increases in levels of lymphocytes, indi-
cated by the presence of OX-19 (CD5)1, OX-38 (CD4)1,
OX-8 (CD8)1, and 10/78 (NKR-P1)1 cells were observed
in glomeruli and peaked on day 7 after injection of mAb
1-22-3 (Fig. 1). In the double-staining study, OX-381 cell
were also stained with OX-19 (Fig. 2A). On the other
hand, almost all CD81 cells in glomerulus were also
stained with 10/78 (Fig. 2C) and were negative for
OX-19 (Fig. 2B). At this time point, part of NKR-P11
cells were stained by the antiperforin mAb (Fig. 2D).
Significant decreases in total numbers of mononuclear
cells, total T cells (CD51 cells), CD41 cells, CD81 cells,
and NKR-P11 cells after an injection of mAb 1-22-3
were revealed by flow cytometric analysis (Fig. 3). RT-
PCR revealed increased expression of mRNA for lym-
phokines, IFN-g, IL-2, IL-10, and perforin, but not for
IL-4 after an injection of mAb 1-22-3 (Fig. 4). Expression
of the chemokines MCP-1, RANTES, and lymphotactin
also increased (Fig. 4).
Experiment 2: Lymphocyte depletion study
Cell numbers in circulating lymphocyte subpopula-
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Fig. 1. Time course of glomerular infiltration
of lymphocytes after an injection of mono-
clonal antibody (mAb) 1-22-3. Numbers of
lymphocytes per glomerular cross section
were counted in 50 randomly selected full-size
glomeruli, and the results were expressed as
mean 6 SD (N 5 5). Symbols are: (j) OX-19
(CD5)1 cells; ( ) OX-38 (CD4)1 cells; ( )
OX-8 (CD8)1 cells; ( ) 10/78 (NKR-P1)1
cells; *P , 0.05 and **P , 0.01 compared
with before injection.
Fig. 2. Double staining immunofluorescence (IF) studies of rat glomeruli seven days after the induction of glomerulonephritis (GN). (A) Double
staining with anti-CD5 mAb (OX-19) and anti-CD4 mAb (OX-38). All CD51 cells were also stained with anti-CD4 mAb (yellow). (B) Double
staining with OX-19 (red) and anti-CD8 mAb (R1-10B5; green). No double positive cells were detected. (C ) Double staining with R1-10B5 and
anti-NKR-P1 mAb (10/78). All CD81 cells were also stained with anti-NKR-P1 mAb (yellow). (D) Double staining with antirat perforin and
10/78. Part of NKR-P11 cells (red) were also stained with antiperforin (arrowhead, yellow). Original magnification, 3400.
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Fig. 3. Kinetics of the number of circulating lymphocytes after injection of rats with mAb 1-22-3. Symbols are: (s) saline group; (d) mAb 1-22-3
group. Absolute subset numbers were calculated using leukocyte counts, and the proportions of subsets were determined by flow cytometry.
Significant reductions of circulating total mononuclear cells (A), CD5 (OX-19)1 cells (B), CD4 (OX-38)1 cells (C ), CD8 (OX-8)1 cells (D), and
NKR-P1(10/78)1 cells (E ) were observed by day 14 after injection of mAb 1-22-3. Values are expressed as mean 6 SD (N 5 5). *P , 0.05 and
**P , 0.01 compared with saline-injected controls.
summarized in Table 2. In peripheral blood, anti-CD5 lymphocyte populations in control (RVG1)-treated rats
were unaffected.mAb (OX-19) treatment caused marked reductions in
the numbers of CD51 and CD41 cells, which were main- The change in degree of proteinuria over time is illus-
trated in Figure 5. Significant reduction of proteinuriatained until the end of the experiment. Treatment with
anti-CD4 mAb (OX-38) also reduced the number of on days 5, 7, and 10 was observed in the anti-CD5 mAb
(OX-19) and anti-CD4 mAb (OX-38)–treated groups.CD41 cells; however, the effect was mild compared with
that of anti-CD5 mAb treatment. Anti-CD8 mAb (OX-8) A comparison of mesangial injury evaluated by total num-
ber of cells in glomeruli, matrix score, collagen type Iaffects the numbers of both CD81 cells and NKR-P11
cells but had no effect on CD41 cell count. Circulating staining score, a-SMA staining score, and kidney weight
Fig. 4. Expression of rat glomerular mRNA for lymphokines and chemokines after injection with mAb 1-22-3. The data shown are representative
semiquantitative measurements made by RT-PCR amplification of mRNA from five rats. mRNA from five rats sacrificed at each time point was
pooled and used for RT-PCR. The representative agarose gel electrophoretic patterns from one of three independent experiments are shown at
top. Ratios of the densitometric signals of cytokines to that of the internal control (GAPDH) were computed. A weak signal was detected in
normal control rats for all cytokines studied. The data are shown as ratios relative to normal rat findings and are expressed as mean 6 SD of
three independent experiments. Increased expression for lymphokines (A, B, D, and E ), except for IL-4 (C ), and those for chemokines (F–H)
was detected after induction of Thy 1.1 GN.
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on day 14 is summarized in Figure 6. Reduced mesangial
injury was observed only in the anti-CD5 mAb (OX-19)–
treated group (Figs. 6 and 7). Although anti-CD8 mAb
treatment reduced the recruitment of CD81 cells (0.061 6
0.017 vs. 4.58 6 0.82, P , 0.01) and NKR-P11 cells (0.11 6
0.062 vs. 4.26 6 1.06, P , 0.01) seven days after in-
duction of GN, no significant changes was observed in
the anti-CD8 mAb-treated group compared with the
control group.
Further analysis of the effects of anti-CD5 mAb
(OX-19) treatment
To ascertain whether the anti-CD5 mAb treatment
might interfere with the binding of mAb 1-22-3 to kidney,
the radioactivity of 125I-labeled mAb 1-22-3 was mea-
sured in a g-counter. In the group of rats treated with
anti-CD5 mAb, the mean amount of mAb 1-22-3 bound
in a kidney was 7.84 6 0.54 mg, which was comparable
to the 7.92 6 0.079 mg bound to kidney in the RVG1-
treated control group, and there were no significant
differences between these two groups (P 5 0.51). To
exclude the possibility that anti-CD5 mAb treatment
interferes with the fixation of complement in glomeruli,
we used the autoexposure system to measure fluores-
cence intensities of FITC-conjugated antirat C3 in glo-
meruli from rats 30 minutes after an injection of mAb
1-22-3. There were no differences in exposure time for
the fluorescence intensities of FITC-conjugated C3 depo-
sition in the glomeruli (9.37 6 1.25 vs. 9.52 6 1.24 s, P 5
0.85). The serum CH50 values just before an injection
of mAb 1-22-3 (50.23 6 1.48 vs. 49.18 6 2.06 U/mL, P 5
0.44) and after an injection of mAb 1-22-3 (35.58 6
2.69 vs. 33.58 6 1.18 U/mL, P 5 0.22) also showed no
significant difference between the initiation of anti-CD5
mAb treatment and control group.
The IF study revealed that treatment of rats with anti-
CD5 mAb affected glomerular accumulation of CD41
cells, whereas this treatment did not influence the num-
ber of NKR-P11 cells. In addition, anti-CD5 mAb treat-
ment did not influence the number of ED11 cells (pan
monocytes/macrophages), but a significant reduction of
ED31 cells (activated macrophages) was observed (Fig. 8).
To examine the cytokine profile, mRNA from isolated
glomeruli was compared with that from the control group
(Fig. 9). GAPDH RT-PCR data confirmed that similar
concentrations of cDNA were analyzed from each sam-
ple. Anti-CD5 mAb treatment suppressed expression
of glomerular IL-2 mRNA through the experimental
period. mRNA expression for IFN-g was reduced on
day 14. This treatment did not reduce the glomerular
expression of IL-10 or perforin mRNA. Glomerular ex-
pression of PDGF or TGF-b mRNA increased immedi-
ately after an injection of mAb 1-22-3; however, anti-
CD5 mAb had no effect on glomerular expression of
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Fig. 5. Effects of anti-CD5 mAb (OX-19; A and B), anti-CD4 mAb (OX-38; C and D) and anti-CD8 mAb (OX-8; E and F ) treatment on kinetics
of proteinuria in rats after injection of mAb 1-22-3. A significant reduction of proteinuria was observed in the anti-CD5 mAb– and anti-CD4
mAb–treated group. Each study was carried out twice and followed for 7 (B, D, and F) or 14 (A, C, and E) days after injection of mAb 1-22-3.
Symbols are: (s) control group; (3) anti-CD5 mAb (OX-19)-treated group; (r) anti-CD4 mAb (OX-38)-treated group; (.) anti-CD8 mAb
(OX-8)-treated group. The results are expressed as mean 6 SD (N 5 5). *P , 0.05 and **P , 0.01 compared with the control group at the same
time point.
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Fig. 6. Effect of lymphocyte depletion on rat glomerular changes. Glomerular changes evaluated by total number of cells per glomerular cross
section (c/gcs) (A), matrix expansion (B), collagen type I staining score (C ), a-smooth muscle actin (a-SMA) staining score (D), and kidney weight
(E ) were compared between the lymphocyte-depleted group and the control group on day 14. Each value is expressed as mean 6 SD (N 5 5).
Symbols are: ( ) control group; (j) anti-CD5 mAb treated group; ( ) anti-CD4 mAb treated group; ( ) anti-CD8 mAb treated group; *P ,
0.05; **P , 0.01.
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Fig. 7. Micrographs of periodic acid-Schiff (PAS)-stained kidney sections from rats treated with anti-CD5 mAb (OX-19; A) and from a control
(RVG1-treated) group (B) 14 days after injection of mAb 1-22-3. Original magnification, 3200.
Reverse transcription-PCR analysis using glomerular were no inflammatory lesions in any other organs to
RNA from individual rat also demonstrated that both which mAb 1-22-3 binds, such as thymus, lymph nodes,
IL-2 (0.80 6 0.29 vs. 2.03 6 1.55, P , 0.01) and IFN-g spleen, liver, or intestines. These observations indicate
mRNA expression (0.42 6 0.13 vs. 0.64 6 0.15, P , 0.05) that circulating lymphocytes are recruited into the in-
were reduced in the anti-CD5 mAb-treated group on flammatory site of the kidney after an injection of mAb
day 14. 1-22-3. RT-PCR study demonstrated that the expression
of glomerular mRNA for certain cytokines that are con-
sidered to be produced by lymphocytes, such as IFN-g,DISCUSSION
IL-2, IL-10, and perforin, increased after mAb 1-22-3
Previously, we reported that increased numbers of injection. These findings also supported that idea that
lymphocytes were observed in the mesangial area in Thy lymphocytes are recruited into glomeruli.
1.1 GN on electron microscopy [20]. These lymphocytes Thy 1.1 GN is induced by passive injection of anti-
in the mesangial area seem to be involved in mesangial
Thy 1.1. mAb without immunization with specific anti-
cell proliferation and the consequent alterations to the
gen. The mechanism of the recruitment of T lymphocytesmesangium. In this study, we elucidated the role of vari-
and NK cells into glomeruli is unclear in this GN model.ous lymphocytes in the development of Thy 1.1 GN.
It was reported that certain chemokines could attract TIF studies with mAbs that recognize subpopulations of
lymphocytes to the inflammatory site without specificlymphocytes revealed that numerous CD8 (OX-8) and
antigen presentation [40, 41]. Several studies showed thatNKR-P1 (10/78)-positive cells were recruited into glo-
MCP-1 and RANTES could attract CD41 and CD81 Tmeruli beginning just after anti-Thy 1.1 mAb injection.
lymphocytes, while lymphotactin is considered to be theInfiltration of T lymphocytes recognized by anti-CD5
chemoattractant specific for CD81 T lymphocytes andmAb (OX-19) or anti-CD4 mAb (OX-38) was also de-
NK cells [21–23]. In this study, we revealed that expres-tected, which were fewer than CD81 or NKR-P11 cells.
sion of glomerular mRNA for the chemokines MCP-1,OX-8 is reported to recognize both CD81 T lymphocytes
RANTES, and lymphotactin increases. Recently, it wasand NK cells in rats [8, 10, 38, 39]. Double-staining IF
reported that both MCP-1 and RANTES can activate Tstudy revealed that most OX-81 cells detected in glomer-
lymphocytes without involving T-cell antigen receptoruli were NK cells rather than CD81 T lymphocytes (Fig.
signaling [41–43]. Stahl et al reported that MCP-1 was2C) and that almost all T lymphocytes (CD51 cells) infil-
produced by mesangial cells that were stimulated by anti-trated in glomeruli were CD41 T lymphocytes (Fig. 2A).
Thy 1.1 antibody binding [44]. Thus, it is conceivableFrom these findings, we concluded that mainly NK cells
that non–antigen-specific T lymphocytes are recruitedand CD41 T lymphocytes infiltrate glomeruli in Thy 1.1
by the chemokines from glomerular cells.GN. Flow cytometric analysis showed that the number
In this study, we demonstrated that the numerous NKof circulating lymphocytes decreased after an injection
of mAb 1-22-3. Our previous study revealed that there cells were recruited in glomeruli. A double-staining IF
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Fig. 8. Effects of anti-CD5 mAb (OX-19) treatment on rat glomerular leukocyte accumulation after an injection of mAb 1-22-3. Time course of
the extent of glomerular infiltration by OX-19 (CD5)1, OX-38 (CD4)1, OX-8 (CD8)1, and 10/78 (NKR-P1)1, ED11, and ED31 cells was compared
between the anti-CD5 mAb-treated group (j) and the RVG1-treated control group ( ) by IF staining. Values are expressed as mean 6 SD.
*P , 0.05; **P , 0.01 compared with the control group at the same time point.
study revealed that most NK cells in glomeruli produced matrix score, a-SMA staining score, and collagen type
I staining, as well as by increased kidney weight on dayperforin, a major participant in the lytic machinery of
cytotoxic lymphocytes [45]. However, anti-CD8 mAb 14 after induction of Thy 1.1 GN (Figs. 5 and 6). We
believe that these findings indicate that anti-CD5 mAb(OX-8) treatment had no protective effect on proteinuria
(Fig. 5) or any morphological parameters (Fig. 6). IF treatment suppresses mesangial cell proliferation and
consequent mesangial matrix expansion. Anti-CD4 mAbfindings showed that anti-CD8 mAb treatment com-
pletely prevented the recruitment of NK cells into glo- treatment also reduced proteinuria but did not suppress
mesangial injury. Because double-staining IF findingsmeruli. These findings indicating that NK cells did not
play an active role in the pathogenesis of Thy 1.1 GN. indicated that most T lymphocytes in glomeruli are of
the CD41 subtype (Fig. 2A), it is unclear why only anti-On the other hand, anti-CD5 mAb (OX-19) treatment
clearly reduced proteinuria and reduced the mesangial CD5 mAb (OX-19) but not anti-CD4 mAb (OX-38)
treatment prevents mesangial injury. It might be ex-injury, as evaluated by total number of cells in glomeruli,
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Fig. 9. Effect of anti-CD5 mAb (OX-19) treatment on rat glomerular mRNA expression for cytokines after Thy1.1 GN induction. mRNA
expression for cytokines was measured by RT-PCR on total RNA pooled from five rats from anti-CD5 mAb-treated group (GN) and RVG1-
treated control group ( ). The ratios of the densitometric signals of cytokine mRNA relative to the internal control (GAPDH) were computed.
The data are shown as ratios relative to normal rat findings and expressed as mean 6 SD.
plained by the difference in efficiency of depletion of was not as effective, and CD41 T-lymphocyte levels re-
covered earlier after this treatment than after anti-CD5CD41 T lymphocytes by OX-19 and OX-38. Flow cyto-
metric analysis showed that anti-CD5 mAb treatment mAb treatment (Table 2). Some other reports have also
mentioned difficulty in depleting CD41 T lymphocytesreduced the number of circulating CD41 T lymphocytes
to around 20% and that this suppression was maintained with anti-rat CD4-specific mAbs [28, 46]. Thus, it is con-
sidered that the effect of treatment with OX-38 mightthroughout the experiment (Table 2). However, CD41
T lymphocyte depletion by anti-CD4 mAb treatment not be sufficient to reduce the mesangial injury as evalu-
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ated on day 14. However, we cannot completely rule out ular injury in Thy1.1 GN in rat, which suggests that T
lymphocytes contribute to the pathogenesis of humanthe possibility that OX-191/OX-382 cells contribute to
the development of mesangial injury. proliferative GN.
The mechanism of the protective effect of anti-CD5
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